Pfizers calls on asset managers prove fruitless
Pfizers attempt to coax AstraZeneca’s major shareholders into forcing its board to negotiate on a potential takeover ultimately come to nothing
Equities
-
-
Fidelity targets index tracker dominance
Fidelity Worldwide Investments has cut the costs of its equity range of index products in an effort to become the dominant player in the space.
-
Heaven help the equity underperformers
With investors on the lookout for any signs that valuations wont be backed by earnings corporates cannot be seen to be underperforming.
-
BlackRock weighs in on AstraZeneca
Blackrock has publicly urged the AstraZeneca board to re-engage with potential buyer Pfizer
-
EU elections not expected to trouble markets
Results of European elections under way today are very unlikely to cause major disruption in markets, fund managers have said
-
Market optimism still dampened by EM worries
Periodic mini-crises have forced central banks to take aggressive action to shore up their currencies, often at the expense of the outlook for domestic growth, writes Threadneedle’s Mark Burgess.
-
River and Mercantile confirms London IPO plan
Company planning to raise £12m through London Stock Exchange IPO
-
Six core funds for playing the long game
David McFadzean of RBC Wealth Management favours the long game and looks at six funds that help balance a portfolio.
-
RSMR launches fund range and SRI ratings
Rayner Spencer Mills Research is launching fund range and SRI rating services
-
LSE enters exclusive talks on Russell deal
London Stock Exchange says it has entered exclusive talks with The Northwestern Mutual Life Insurance Company on buying Russell Investments
-
Woodford applauds AstraZeneca board
Woodford applauds the AstraZeneca board’s handling of Pfizers takeover approach
-
Smith and Williamson launches new EM value fund
Smith & Williamson are hoping that the thawing of sentiment towards emerging markets will continue as it launches a new Emerging markets Value Fund.